In 2013, Inez de Greef – van der Sandt was appointed as CEO for our client Treeway, a biotechnology company with a mission to develop therapies to cure ALS. 

Treeway is a clinical-stage biotechnology company with a mission to develop therapies to cure ALS. It was founded in 2012 by two ALS patients, Bernard Muller and Robbert Jan Stuit. Treeway aims to develop drugs that first delay disease progression, followed by therapies that halt or control the disease finally leading to a breakthrough therapy to cure ALS. Currently, Treeway has established a pipeline consisting of two drug therapies, TW001 and TW002, which are in development and is assessing several research lines to validate drugable targets.

In its mission to identify compounds and develop therapies that have the potential to fully halt disease progression, Treeway closely collaborates with (global) research and clinical institutes, and is involved in establishing the grounds for TRICALS, a European institute for performing clinical trials specifically in ALS. Treeway’s founders also initiated Project MinE, the world’s largest-scale research initiative devoted to discovering the genetic cause of ALS. Although Treeway is a young biotech company, it has established relationships with ALS researchers and doctors globally. In addition, Treeway has realized a strong patient empowerment within the target market, which makes Treeway a leader within this therapeutic area.

e info@3d-pxc.com
t +31 1 353 482 72

Maidstone 48a, 5026 SK Tilburg,
The Netherlands

Pivot Park, RK Building, room 2326,
Kloosterstraat 9,
5349 AB Oss,
The Netherlands

© 3D-PharmXchange 2020
Privacy statement

Our solutions

Navigating milestones successfully is critical for your drug development program to move forward. Besides a focus on quality, our teams aim to ensure that your plans are executed efficiently, cost-effectively, and are ready to partner with you to develop a program customized to your needs. 

Our senior experts can also take on leadership roles to answer to your development program’s specific requirements. Whether they are Non-Clinical, Clinical, CMC, or Regulatory experts they all have hands-on experience with leading large development teams and toward market approval.

Read more about our Leadership Roles.

Non-Clinical

Samenvattende tekst

CMC

Samenvattende tekst

Clinical

Samenvattende tekst

Regulatory Affairs

Samenvattende tekst

Leadership Roles

Our senior experts are selected based on their ability to answer to your development program’s specific requirements. Whether they are Non-Clinical, Clinical, CMC, or Regulatory experts they all have hands-on experience with leading large development teams and toward market approval.

Without exception, we are concerned with the seniority and experience of our candidates required to lead multi-disciplinary teams and to provide you with a balanced expert collaboration that matches your needs.

About us

A company where small dedicated teams and a high level of ownership are the key to success. That is why we treat our clients’ project as if they are our own. From a genuine interest we maintain a close relationship with our clients, in which we value open and honest communication, in order to provide high quality tailored solutions.

Main Office
Maidstone 48a
5026 SK Tilburg
The Netherlands

Satellite Office
Pivot Park RK Building Room 2326
Kloosterstraat 9
5349 AB Oss
The Netherlands

Careers at 3D

No drug is developed by a single person. We understand that it takes teamwork, perseverance to realize something this big. The 3D team works hard with room to laugh and is looking to expand.

At 3D, we believe knowledge needs to be shared to further develop clinical programs, increase market access, and to meet unmet patient needs. This is why we share publications, blogs, and other insights here. Feel free to leave us a message if you’d like more information on a certain topic.